Cardiac Amyloidosis Market Size, Share & Trends Analysis Report By Product | Forecast to 2029
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
How Will The Cardiac Amyloidosis Market Valuation Change Between Now And 2029?
In the past few years, the market size for cardiac amyloidosis has seen robust growth. The market, which is projected to amount to $5.26 billion in 2024, is expected to expand to $5.73 billion by 2025, exhibiting a compound annual growth rate (CAGR) of 8.9%. The significant growth during the historical period is due to several factors including an increase in the number of amyloidosis-related conditions, heightened incidence of genetic mutations, growing awareness, a rise in the number of transthyretin amyloidosis cases, as well as an expanding geriatric population.
In the coming years, the market size for cardiac amyloidosis is projected to experience substantial growth. It is estimated to reach $8.03 billion by 2029, with a compound annual growth rate (CAGR) of 8.8%. This growth during the forecast period can be attributed to factors such as higher diagnosis rates, government influences and initiatives, a surge in genetic mutations instances, and programs aimed at helping patients. The projected period will also see significant trends including the development of therapies like vulrisiran, increased research in gene therapy, a shift towards precision medicine, improvements in diagnostic technology, and the creation of new treatments.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21128&type=smp
What Underlying Factors Are Supporting The Cardiac Amyloidosis Market Growth?
The anticipated growth of the cardiac amyloidosis market is largely due to the rapidly expanding geriatric population. This population segment refers to individuals aged 65 and above who often need specialized healthcare and support due to changes with age. This group is expanding as a result of increasing life expectancy, improved healthcare, and lower birth rates. This increased geriatric population means more instances of cardiac amyloidosis, given that amyloid protein build-up in the heart is often associated with aging. For instance, the Population Reference Bureau, a US nonprofit organization, estimated in January 2024 that the US population of those aged 65 and older would jump from 58 million in 2022 to 82 million by 2050, an increase of 47%. Consequently, the expanding geriatric population will drive the cardiac amyloidosis market forward.
Which Sub-Segments Are Driving Growth Within The Cardiac Amyloidosis Market?
The cardiac amyloidosismarket covered in this report is segmented –
1) By Product Type: Light Chain Amyloidosis; Transthyretin Amyloidosis
2) By Treatment: Chemotherapy; Surgery; Supportive Care; Stem Cell Transplant; Targeted Therapy
3) By End-User: Hospitals; Ambulatory Surgical Centres; Clinics
Subsegments:
1) By Light Chain Amyloidosis: Immunoglobulin Light Chain (AL) Amyloidosis; Primary Light Chain Amyloidosis; Secondary Light Chain Amyloidosis
2) By Transthyretin Amyloidosis: Hereditary Transthyretin Amyloidosis (ATTRm); Wild-type Transthyretin Amyloidosis (ATTRwt)
What Current And Upcoming Trends Are Shaping The Cardiac Amyloidosis Market?
Major corporations in the cardiac amyloidosis market are concentrating their efforts on technological advancements, such as artificial intelligence (AI)-based diagnostic applications, in order to facilitate early detection and better clinical results for patients suffering from this often undetected disease. A diagnostic device that is software-based and uses AI to detect cardiac amyloidosis is devised to scrutinize echocardiographic images and pinpoint symptoms of the disease, without the need for extra hardware or in-depth clinical information. To illustrate, Ultromics Ltd., a health tech company based in the UK, acquired FDA approval for EchoGo Amyloidosis, an AI-enhanced clinical device purposed for early detection of cardiac amyloidosis, in November 2024. It is the inaugural device in the FDA’s Total Product Lifecycle Advisory Program (TAP) to be granted marketing authorization. EchoGo Amyloidosis employs artificial intelligence to examine echocardiograms in order to identify the disease using just a single clip, addressing the critical need for earlier diagnosis before the disease advances undetected.
Which Companies Hold A Competitive Edge In The 1371 Market?
Major companies operating in the cardiac amyloidosis market are Pfizer Inc., Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Alexion Pharmaceuticals Inc., Dr. Reddy’s Laboratories, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc., BridgeBio Pharma Inc., Prothena Corp, Intellia Therapeutics Inc., Amylyx Pharmaceuticals, Neurimmune AG, SOM Biotech, Oncopeptides, Attralus Inc., Eidos Therapeutics.
Access The Complete Report Here:
https://www.thebusinessresearchcompany.com/report/cardiac-amyloidosis-global-market-report
Which Region Dominates The Cardiac Amyloidosis Market Today?
North America was the largest region in the cardiac amyloidosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac amyloidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=21128&type=smp
Browse Through More Reports Similar to the Global Cardiac Amyloidosis Market 2025, By The Business Research Company
Cardiac Pacemakers Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/cardiac-pacemakers-global-market-report
Cardiac Valve Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/cardiac-valve-global-market-report
Cardiac Arrhythmia Monitoring Devices Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
